181P: Anti-PD-1 antibodies in non-small cell lung cancer (NSCLC): The real-life setting experience

Journal of Thoracic Oncology

Volumn 11, Issue 4, 2016, Pages S136-

  Dudnik, E ^a   Moskovitz, M ^b   Wollner, M ^c   Zer, A ^a   Bar, J ^d   Agbarya, A ^e   Idan, T ^f   Shechtman, Y ^b   Amna, M Abu ^c   Peled, N ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b Rambam Health Care Campus   (Israel)

^c Rambam Health Care Center   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

^e ASSUTA MEDICAL CENTER   (Israel)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

NIVOLUMAB; PEMBROLIZUMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CROHN DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEX RATIO; SMOKING; SURVIVAL TIME;

EID: 85020484490     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/S1556-0864(16)30291-X     Document Type: Article

References (0)